Quincy Bioscience Earns NSF GMP Registration for Facilities
News Jul 18, 2013
Quincy Bioscience announced today that its Pinehurst manufacturing facility is now a Good Manufacturing Practices (GMP) facility registered by NSF International.
Earning GMP registration from NSF International verifies that Quincy Bioscience’s facility has the proper methods, equipment, facilities, and controls in place for producing dietary supplement products. The NSF GMP’s were developed in accordance with the U.S. Food and Drug Administration’s (FDA) 21 CFR part 111 regulation on dietary supplement manufacturing, packaging, and distribution. Utilizing GMP guidelines assists companies in developing and maintaining proper controls in their manufacturing process so that products are processed, manufactured and labeled in a consistent manner, and meet quality standards.
"Earning NSF GMP registration for their Pinehurst manufacturing facility provides Quincy Bioscience with a system for continual improvement, as well as demonstrates to customers and supply chain partners their commitment to quality and safety," said Ed Wyszumiala, General Manager of NSF International’s Dietary Supplement programs.
"We’re proud to achieve this recognition of our manufacturing facilities," says Mark Underwood, President of Quincy Bioscience. "We take good manufacturing practices very seriously, and we look forward to continuing our practice of excellence."
Quincy Bioscience manufactures Prevagen, the #1 selling brain health supplement in chain drug pharmacies. Prevagen contains the main ingredient 'apoaequorin', a protein originally discovered in a jellyfish which is used to improve mild memory loss associated with aging.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE